Oncopig and Human Bladder Cancer Cell Lines: Control vs Gemcitabine Treated
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA1073916 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Transcriptional profiling of Oncopig and human bladder cancer cell lines comparing control untreated cells to cell treated with gemcitabine for 48 hours. Goal was to compare similar transcriptional alterations in response to gemcitabine treatment across both species
2024-02-16 | GSE255187 | GEO
Project description:In this research, Human OneArray Microarray analysis was performed to obtain broad spectrum information about the genes differentially expressed in human bladder cancer cell line RT112 and Gemcitabine Resistant Bladder Cancer cell line RT112-Gr.
2015-04-16 | E-MTAB-3495 | biostudies-arrayexpress
Project description:Advanced bladder cancer is treated mainly with gemcitabine and cisplatin, but most patients eventually become resistance to these chemotherapeutic agents. Androgen receptor (AR) signaling has been implicated in bladder cancer as well as other types of cancer including prostate cancer. In the present study, we showed the expression and role of AR in gemcitabine-resistant bladder cancer cells and examined the potential of enzalutamide, an AR inhibitor, as a therapeutic for the chemoresistance. First of all, we established gemcitabine-resistant T24 cells (T24GR) from T24 bladder cancer cells and performed gene expression profiling and network analysis, which revealed increased AR expression and AR-related gene network in T24GR cells. Quantitative RT-PCR and Western blot analysis confirmed increased expression of AR in T24GR cells compared with parental T24 cells, which was associated with more potent transcriptional activity of AR in T24GR cells. The number of AR gene copy in T24GR cells was twice as many as that of T24 cells. Knockdown of AR expression by siRNA resulted in inhibition of proliferation of T24GR cells. Cell culture in charcoal-stripped serum and treatment with enzalutamide also inhibited growth of T24GR cells, which was accompanied by cell cycle arrest. Lastly, the AR transcriptional activity was found to be reduced in T24GR cells by enzalutamide treatment. Our results suggest that blockade of AR signaling by enzalutamide might be effective for patients with advanced gemcitabine-resistant bladder cancer with increased AR expression.
2016-11-30 | GSE77883 | GEO
Project description:Chemotherapy is often combined with surgery for muscle invasive and non-muscle invasive bladder cancer. However, 70% of the patients recur within 5 years. Metabolic reprogramming is an emerging hallmark in cancer chemoresistance. Here, we report a gemcitabine resistance mechanism which promotes cancer reprogramming via the metabolic enzyme, OXCT1. This mitochondrial enzyme, responsible for the rate-limiting step in β-hydroxybutyrate (βHB) catabolism, was elevated in muscle invasive disease and in chemo-resistant bladder cancer patients. Resistant orthotopic tumors presented an OXCT1-dependent rise in mitochondrial oxygen consumption rate, ATP, and nucleotide biosynthesis. In resistant bladder cancer, knocking out OXCT1 restored gemcitabine sensitivity, and administering the non-metabolizable βHB, enantiomer (S-βHB) only partially restored gemcitabine sensitivity. Suggesting an extra-metabolic role for OXCT1, multi-omics analysis of gemcitabine sensitive and resistant cells revealed an OXCT1-dependent signature with the transcriptional repressor, OVOL1, as a master regulator of epithelial differentiation. The elevation of OVOL1 target genes was associated with its cytoplasmic translocation and poor prognosis in a chemotherapy-treated BCa patient cohort. The knockout of OXCT1 restored OVOL1 transcriptional repressive activity by its nuclear translocation. Orthotopic mouse models of bladder cancer supported OXCT1 as a mediator of gemcitabine sensitivity through ketone metabolism and regulating cancer stem cell differentiation.
2025-01-02 | GSE280095 | GEO
Project description:Gemcitabine is commonly used for the treatment of PDAC, here we assess the effect of gene expression in human PDAC cell lines.
2023-12-05 | GSE249302 | GEO
Project description:40 bladder cancer cell lines were profiled with their genome-wide gene expression patterns using Affymetrix HG-U133A chips. Keywords: bladder cancer cell line expression profiling
2009-08-26 | GSE5845 | GEO
Project description:Mitomycin C (MMC) is the gold standard treatment for non-muscle invasive bladder cancer (NMIBC). We aimed to evaluate in bladder cancer cell lines (T24, 5637, TCC-SUP and CLS-439) the transcriptomic response to MMC treatment. We used Gene Set Enrichment Analysis (GSEA) to identify biological processes and pathways modulated by MMC treatment.
2021-01-02 | GSE151505 | GEO
Project description:Therapeutic options for metastatic or recurrent osteosarcoma are limited. Gemcitabine and 12 docetaxel combination is used as second-line therapy for this disease. Bromodomain-containing 13 protein 4 (BRD4) plays essential roles in regulating autophagy in several human diseases and is 14 overexpressed in osteosarcoma. Thus, in the current study, we investigated whether BRD4 is 15 involved in the modulation of gemcitabine-induced autophagy in osteosarcoma. We confirmed 16 that gemcitabine induced autophagic flux in LM7 and CCH-OS-D human osteosarcoma cell lines. 17 Furthermore, we found that gemcitabine induced BRD4 protein and mRNA expression in a time-18 dependent manner in LM7 cells and also in CCH-OS-D cells but only at the mRNA level. Moreover, 19 gemcitabine induced CCAAT/enhancer binding protein beta (C/EBPβ), a transcription factor 20 known to regulate autophagy. We further showed that C/EBPβ induction was mediated by BRD4 21 as inhibition of BRD4 blocked its induction. Furthermore, we demonstrated that gemcitabine-22 induced C/EBPβ bound to BRD4. Because inhibition of BRD4 diminished autophagic flux, we 23 conclude that BRD4 may act as an epigenetic regulator of gemcitabine-induced autophagy in 24 osteosarcoma via C/EBPβ. Additionally, because inhibition of BRD4 in gemcitabine treated 25 osteosarcoma cells led to different outcomes, our data suggests the potential for the BRD4- 26 C/EBPβ interaction to define gemcitabine-induced autophagy outcome in osteosarcoma.
2025-12-31 | GSE255956 | GEO
Project description:Pancreatic cancer cells (MIA PaCa-2) were treated with Gemcitabine and overall protein changes were studied
2022-09-15 | PXD030861 | Pride
Project description:Gemcitabine resistance is currently the main problem of chemotherapy for advanced pancreatic cancer patients. The resistance is thought to be caused by altered drug metabolism or reduced apoptosis of cancer cells. However, the underlying mechanism of Gemcitabine resistance in pancreatic cancer remains unclear. In this study, we established Gemcitabine resistant PANC-1 (PANC-1-GR) cell lines and compared the circular RNAs (circRNAs) profiles between PANC-1 cells and PANC-1-GR cells by RNA sequencing.
2019-07-07 | GSE110580 | GEO